1. Rotz SJ; Dandoy CE; Davies SM. ST2 and Endothelial Injury as a Link between GVHD and Microangiopathy. The New England journal of medicine. 2017; 376:1189-1190.
  2. de la Morena MT; Leonard D; Torgerson TR; Cabral-Marques O; Slatter M; Aghamohammadi A; Chandra S; Murguia-Favela L; Bonilla FA; Kanariou M. Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation. Journal of Allergy and Clinical Immunology. 2017; 139:1282-1292.
  3. Chandrakasan S; Marsh RA; Uzel G; Holland SM; Shah KN; Bleesing J. Outcome of patients with NEMO deficiency following allogeneic hematopoietic cell transplant. Journal of Allergy and Clinical Immunology. 2017; 139:1040-1043.e2.
  4. Rubin TS; Zhang K; Gifford C; Lane A; Choo S; Bleesing JJ; Marsh RA. Perforin and CD107a testing is superior to NK cell function testing for screening patients for genetic HLH. Blood. 2017; 129:2993-2999.
  5. Lounder DT; Khandelwal P; Dandoy CE; Jodele S; Grimley MS; Wallace G; Lane A; Taggart C; Teusink-Cross AC; Lake KE. Lower levels of vitamin A are associated with increased gastrointestinal graft-versus-host disease in children. Blood. 2017; 129:2801-2807.
  6. Mehta PA; Davies SM; Leemhuis T; Myers K; Kernan NA; Prockop SE; Scaradavou A; O'Reilly RJ; Williams DA; Lehmann L. Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study. Blood. 2017; 129:2308-2315.
  7. Holtan SG; Khera N; Levine JE; Chai X; Storer B; Liu HD; Inamoto Y; Chen GL; Mayer S; Arora M. Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. Blood. 2016; 128:2350-2358.
  8. Khoury HJ; Wang T; Hemmer MT; Couriel D; Alousi A; Cutler C; Aljurf M; Battiwalla M; Cahn JY; Cairo M. Improved survival after acute graft-versus-host disease diagnosis in the modern era. Haematologica: the hematology journal. 2017; 102:958-966.
  9. Lazaryan A; Wang T; Spellman SR; Wang HL; Pidala J; Nishihori T; Askar M; Olsson R; Oudshoorn M; Abdel-Azim H. Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research. Haematologica: the hematology journal. 2016; 101:1267-1274.
  10. Shaw MA; Gao Z; McElhinney KE; Thornton S; Flick MJ; Lane A; Degen JL; Ryu JK; Akassoglou K; Mullins ES. Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2017; 37:3776-3788.
  11. El-Jawahri A; Chen YB; Brazauskas R; He N; Lee SJ; Knight JM; Majhail N; Buchbinder D; Schears RM; Wirk BM. Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation. Cancer. 2017; 123:1828-1838.
  12. Dandoy CE; Hausfeld J; Flesch L; Hawkins D; Demmel K; Best D; Osterkamp E; Bracke T; Nagarajan R; Jodele S. Rapid cycle development of a multifactorial intervention achieved sustained reductions in central line-associated bloodstream infections in haematology oncology units at a children's hospital: a time series analysis. BMJ Quality and Safety. 2016; 25:633-643.
  13. Chirieleison SM; Marsh RA; Kumar P; Rathkey JK; Dubyak GR; Abbott DW. Nucleotide-binding oligomerization domain (NOD) signaling defects and cell death susceptibility cannot be uncoupled in X-linked inhibitor of apoptosis (XIAP)-driven inflammatory disease. The Journal of biological chemistry. 2017; 292:9666-9679.
  14. Rebecca AM. Diagnostic dilemmas in HLH: Can T-cell phenotyping help?. European Journal of Immunology. 2017; 47:240-243.
  15. Dietz AC; Mehta PA; Vlachos A; Savage SA; Bresters D; Tolar J; Boulad F; Dalle JH; Bonfim C; de la Fuente J. Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 2017; 23:726-735.
  16. Lounder DT; Khandelwal P; Chandra S; Jordan MB; Kumar AR; Grimley MS; Davies SM; Bleesing JJ; Marsh RA. Incidence and Outcomes of Central Nervous System Hemophagocytic Lymphohistiocytosis Relapse after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 2017; 23:857-860.
  17. Simms-Waldrip TR; Sunkersett G; Coughlin LA; Savani MR; Arana C; Kim J; Kim M; Zhan X; Greenberg DE; Xie Y. Antibiotic-Induced Depletion of Anti-inflammatory Clostridia Is Associated with the Development of Graft-versus-Host Disease in Pediatric Stem Cell Transplantation Patients. Biology of Blood and Marrow Transplantation. 2017; 23:820-829.
  18. Marsh RA; Fukuda T; Emoto C; Neumeier L; Khandelwal P; Chandra S; Teusink-Cross A; Vinks AA; Mehta PA. Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab. Biology of Blood and Marrow Transplantation. 2017; 23:635-641.
  19. Grimley MS; Chemaly RF; Englund JA; Kurtzberg J; Chittick G; Brundage TM; Bae A; Morrison ME; Prasad VK. Brincidofovir for Asymptomatic Adenovirus Viremia in Pediatric and Adult Allogeneic Hematopoietic Cell Transplant Recipients: A Randomized Placebo-Controlled Phase II Trial. Biology of Blood and Marrow Transplantation. 2017; 23:512-521.
  20. Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 2016; 22:2220-2225.
  21. Khandelwal P; Bleesing JJ; Davies SM; Marsh RA. A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide, and Antithymocyte Globulin for Chronic Granulomatous Disease. Biology of Blood and Marrow Transplantation. 2016; 22:2011-2018.
  22. Teusink-Cross A; Davies SM; Danziger-Isakov L; El-Bietar J; Grimley MS. Restrictive Palivizumab Use Does Not Lead to Increased Morbidity and Mortality in Pediatric Hematopoietic Stem Cell Transplantation Patients. Biology of Blood and Marrow Transplantation. 2016; 22:1904-1906.
  23. Khandelwal P; Fukuda T; Mizuno K; Teusink-Cross A; Mehta PA; Marsh RA; Kashuba ADM; Vinks AA; Davies SM. A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses. Biology of Blood and Marrow Transplantation. 2016; 22:1829-1835.
  24. Dandoy CE; Haslam D; Lane A; Jodele S; Demmel K; El-Bietar J; Flesch L; Myers KC; Pate A; Rotz S. Healthcare Burden, Risk Factors, and Outcomes of Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infections after Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 2016; 22:1671-1677.
  25. Ballen K; Woo Ahn K; Chen M; Abdel-Azim H; Ahmed I; Aljurf M; Antin J; Bhatt AS; Boeckh M; Chen G. Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 2016; 22:1636-1645.